Gene therapy: future therapy for erectile dysfunction.

G. Schenk, A. Melman, G. Christ

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Advances in molecular biological techniques, completion of the Human Genome Project, and the ensuing age of molecular medicine, in conjuction with the sum of a decades-long accumulation of knowledge of the physiology of erection and the pathophysiology of erectile dysfunction have converged to make gene therapy for erectile dysfunction a distinct possibility. In short, both the intrinsic complexities of mechanisms responsible for ensuring normal erection and the multifactorial nature of erectile dysfunction ensure that there is a relatively vast number of physiologically relevant molecular targets for gene therapy. As such, perhaps it is not surprising that virtually every preclinical gene therapy strategy/target examined thus far has been largely successful in ameliorating conditions associated with compromised erectile function in vivo and/or in vitro. This report highlights the goals and strategies of gene therapy for erectile dysfunction and reviews the strategies that initially have been employed. In short, the preclinical data, while still quite preliminary in many regards, are nonetheless quite impressive and encouraging. If similar success is obtained in clinical trials, gene therapy for erectile dysfunction may provide the first concrete "proof of concept" for using gene therapy in the treatment of human smooth muscle disorders.

Original languageEnglish (US)
Pages (from-to)480-487
Number of pages8
JournalCurrent Urology Reports
Volume2
Issue number6
StatePublished - Dec 2001

Fingerprint

Erectile Dysfunction
Genetic Therapy
Therapeutics
Molecular Medicine
Human Genome Project
Muscular Diseases
Smooth Muscle
Clinical Trials

ASJC Scopus subject areas

  • Urology

Cite this

Schenk, G., Melman, A., & Christ, G. (2001). Gene therapy: future therapy for erectile dysfunction. Current Urology Reports, 2(6), 480-487.

Gene therapy : future therapy for erectile dysfunction. / Schenk, G.; Melman, A.; Christ, G.

In: Current Urology Reports, Vol. 2, No. 6, 12.2001, p. 480-487.

Research output: Contribution to journalArticle

Schenk, G, Melman, A & Christ, G 2001, 'Gene therapy: future therapy for erectile dysfunction.', Current Urology Reports, vol. 2, no. 6, pp. 480-487.
Schenk G, Melman A, Christ G. Gene therapy: future therapy for erectile dysfunction. Current Urology Reports. 2001 Dec;2(6):480-487.
Schenk, G. ; Melman, A. ; Christ, G. / Gene therapy : future therapy for erectile dysfunction. In: Current Urology Reports. 2001 ; Vol. 2, No. 6. pp. 480-487.
@article{1e9721c1be91447992dcfb191ccd16bf,
title = "Gene therapy: future therapy for erectile dysfunction.",
abstract = "Advances in molecular biological techniques, completion of the Human Genome Project, and the ensuing age of molecular medicine, in conjuction with the sum of a decades-long accumulation of knowledge of the physiology of erection and the pathophysiology of erectile dysfunction have converged to make gene therapy for erectile dysfunction a distinct possibility. In short, both the intrinsic complexities of mechanisms responsible for ensuring normal erection and the multifactorial nature of erectile dysfunction ensure that there is a relatively vast number of physiologically relevant molecular targets for gene therapy. As such, perhaps it is not surprising that virtually every preclinical gene therapy strategy/target examined thus far has been largely successful in ameliorating conditions associated with compromised erectile function in vivo and/or in vitro. This report highlights the goals and strategies of gene therapy for erectile dysfunction and reviews the strategies that initially have been employed. In short, the preclinical data, while still quite preliminary in many regards, are nonetheless quite impressive and encouraging. If similar success is obtained in clinical trials, gene therapy for erectile dysfunction may provide the first concrete {"}proof of concept{"} for using gene therapy in the treatment of human smooth muscle disorders.",
author = "G. Schenk and A. Melman and G. Christ",
year = "2001",
month = "12",
language = "English (US)",
volume = "2",
pages = "480--487",
journal = "Current Urology Reports",
issn = "1527-2737",
publisher = "Current Science, Inc.",
number = "6",

}

TY - JOUR

T1 - Gene therapy

T2 - future therapy for erectile dysfunction.

AU - Schenk, G.

AU - Melman, A.

AU - Christ, G.

PY - 2001/12

Y1 - 2001/12

N2 - Advances in molecular biological techniques, completion of the Human Genome Project, and the ensuing age of molecular medicine, in conjuction with the sum of a decades-long accumulation of knowledge of the physiology of erection and the pathophysiology of erectile dysfunction have converged to make gene therapy for erectile dysfunction a distinct possibility. In short, both the intrinsic complexities of mechanisms responsible for ensuring normal erection and the multifactorial nature of erectile dysfunction ensure that there is a relatively vast number of physiologically relevant molecular targets for gene therapy. As such, perhaps it is not surprising that virtually every preclinical gene therapy strategy/target examined thus far has been largely successful in ameliorating conditions associated with compromised erectile function in vivo and/or in vitro. This report highlights the goals and strategies of gene therapy for erectile dysfunction and reviews the strategies that initially have been employed. In short, the preclinical data, while still quite preliminary in many regards, are nonetheless quite impressive and encouraging. If similar success is obtained in clinical trials, gene therapy for erectile dysfunction may provide the first concrete "proof of concept" for using gene therapy in the treatment of human smooth muscle disorders.

AB - Advances in molecular biological techniques, completion of the Human Genome Project, and the ensuing age of molecular medicine, in conjuction with the sum of a decades-long accumulation of knowledge of the physiology of erection and the pathophysiology of erectile dysfunction have converged to make gene therapy for erectile dysfunction a distinct possibility. In short, both the intrinsic complexities of mechanisms responsible for ensuring normal erection and the multifactorial nature of erectile dysfunction ensure that there is a relatively vast number of physiologically relevant molecular targets for gene therapy. As such, perhaps it is not surprising that virtually every preclinical gene therapy strategy/target examined thus far has been largely successful in ameliorating conditions associated with compromised erectile function in vivo and/or in vitro. This report highlights the goals and strategies of gene therapy for erectile dysfunction and reviews the strategies that initially have been employed. In short, the preclinical data, while still quite preliminary in many regards, are nonetheless quite impressive and encouraging. If similar success is obtained in clinical trials, gene therapy for erectile dysfunction may provide the first concrete "proof of concept" for using gene therapy in the treatment of human smooth muscle disorders.

UR - http://www.scopus.com/inward/record.url?scp=0035553633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035553633&partnerID=8YFLogxK

M3 - Article

C2 - 12084235

AN - SCOPUS:0035553633

VL - 2

SP - 480

EP - 487

JO - Current Urology Reports

JF - Current Urology Reports

SN - 1527-2737

IS - 6

ER -